MedTrace Logo

The Prevalence of Pulmonary Hypertension in Patients With COVID-19.

NCT04459364 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 67

Last updated 2021-01-11

No results posted yet for this study

Summary

The virus infection Covid-19 fills our hospitals and intensive care departments in a very unique way and there is a lack of essential insight into the pathophysiology of the disease. As a result, very specific treatment options are missing. The US Medicines Agency (FDA) has in the last days given a general license for treatment with inhaled nitric oxide (iNO). Inhaled NO in Sweden (and Europe) is approved for the indication of pulmonary hypertension in adults.

However, no one has yet described the occurrence of pulmonary hypertension, with or without right ventricular loading, in the Covid-19 patients who become so seriously ill that they need to be treated at an IVA ward. Knowledge of this is, of course, a prerequisite for determining the need for pulmonary artery catheterization (PA catheter, Swan-Ganz catheter) and also to better understand whether iNO treatment or other forms of lung selective vasodilation therapy may be of benefit to this patient group.

Conditions

  • Hypertension, Pulmonary
  • Right Ventricular Overload
  • COVID

Sponsors & Collaborators

  • Attgeno AB

    lead INDUSTRY

Principal Investigators

  • Per-Arne Lönnqvist, Professor · Karolinska Institutet

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-01
Primary Completion
2020-07-07
Completion
2020-07-15

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04459364 on ClinicalTrials.gov